Thus, MPO impairs vascular function via PVAT inflammation and suppression of vasoprotective mediators, making it a potential therapeutic target in obesity-related cardiovascular disease. The gene discussed is MPO; the disease is obesity due to melanocortin 4 receptor deficiency.